Breast Cancer
Conference Coverage
VIDEO: Dr. William J. Gradishar provides take-home messages from ASCO 2015
Expert gives his take on bevacizumab, T-DM1, palbociclib, and neratinib.
Conference Coverage
Three bisphosphonates found on par in early breast cancer
Key clinical point: Adjuvant zoledronic acid, clodronate, and ibandronate yield similar disease-free survival in early breast cancer. Major...
Conference Coverage
ASCO: Precision medicine initiatives take wing
News
ASCO: Adjuvant neratinib has payoff in HER2-positive breast cancer
Key clinical point: Neratinib reduces the risk of recurrence of invasive disease in women with early HER2-positive breast cancer. Major finding:...
Conference Coverage
Anastrozole provides alternative option for DCIS
Key clinical point: Anastrozole is an alternative option for adjuvant treatment of postmenopausal DCIS. Major finding: Breast cancer–free rates at...
News
ASCO: Enzalutamide advances in triple-negative breast cancer
Key clinical point: Enzalutamide is active in androgen receptor–positive triple-negative breast cancer. Major finding: The 16-week clinical...
News
CDK inhibitor remains active as endocrine resistance emerges
Key clinical point: Palbociclib given with hormonal therapy is efficacious in women with hormone receptor–positive metastatic breast cancer...
Video
VIDEO: Palbociclib may delay chemotherapy for some women with metastatic breast cancer
Audio
David Henry's JCSO podcast, May 2015
News
ASCO 2015: Dr. Hope S. Rugo gives her top picks in breast cancer research
Dr. Hope S. Rugo picks the upcoming ASCO presentations she anticipates to be the most interesting in breast cancer research.